Obi-Wan Kenobi

The Pond Ecosystem to release Layer 2 Blockchain, Magma while Leading the Crypto 2.0 Revolution to Empower the People.

Retrieved on: 
Wednesday, April 3, 2024

The Pond ecosystem was created by the controversial crypto personality Jeremy Cahen AKA @ Pauly0x to give power and value back to the holders.

Key Points: 
  • The Pond ecosystem was created by the controversial crypto personality Jeremy Cahen AKA @ Pauly0x to give power and value back to the holders.
  • What distinguishes Pond0x from other DEX's are the numerous benefits to users of the platform.
  • The Ecosystem will also include it’s Layer 2 blockchain MAGMA which was built to solve many of the current issues faced in the current crypto environment.
  • All the information provided is subject to change at any time due to market conditions or source retractions including editorial modifications.

DriveH2 Green Pre-Oscar Gala Raises Bar for Environmental Advocacy

Retrieved on: 
Thursday, March 14, 2024

EIN, through its research, policy advocacy and public outreach, promotes the widespread adoption of diverse zero-emissions solutions.

Key Points: 
  • EIN, through its research, policy advocacy and public outreach, promotes the widespread adoption of diverse zero-emissions solutions.
  • Brian Goldstein, EIN's Executive Director, commented, "The DriveH2 Green Pre-Oscar Gala grows more impactful each year, drawing attention to elegant solutions like hydrogen fuel cells.
  • We're in the early adopter phase of the hydrogen EV movement, facing challenges like infrastructure development and fuel supply head-on.
  • Hosting the event at the Petersen Automotive Museum was particularly fitting, given its commitment to showcasing the evolution of automotive innovation.”

Give With Heart To Visions Of Possibilities On GivingTuesday 2022

Retrieved on: 
Thursday, November 3, 2022

LOS ANGELES,  November 03, 2022 /PRNewswire-PRWeb/ -- GivingTuesday is a global generosity movement that unleashes the power of radical generosity worldwide. Radical generosity invites people to give what they can to create systemic change. GivingTuesday is a day that encourages and inspires hundreds of millions of people to give, collaborate and celebrate non-profit organizations.

Key Points: 
  • LOS ANGELES, November 03, 2022 /PRNewswire-PRWeb/ -- GivingTuesday is a global generosity movement that unleashes the power of radical generosity worldwide.
  • GivingTuesday is a day that encourages and inspires hundreds of millions of people to give, collaborate and celebrate non-profit organizations.
  • Give With Heart to Visions of Possibilities is our GivingTuesday campaign to encourage supporters of women to contribute to our organization.
  • Visions of Possibilities addresses the importance of uplifting and empowering women through edutainment.

Chukwudi Obi Joins Neil Jacobson's Hallwood Media

Retrieved on: 
Tuesday, May 18, 2021

b'LOS ANGELES, May 18, 2021 /PRNewswire/ -- Hallwood Media, Neil Jacobson\'s writer-producer management company, announced today that Chukwudi Obi has joined the company as Manager.

Key Points: 
  • b'LOS ANGELES, May 18, 2021 /PRNewswire/ -- Hallwood Media, Neil Jacobson\'s writer-producer management company, announced today that Chukwudi Obi has joined the company as Manager.
  • 1\'s Cardi B\'s "Up," produced by Serbia-based producerYung Dza,BTS\' "Dynamite," the K-Pop superstars first-ever English language single, co-written and produced by the London-basedDavid Stewart, andPolo G\'s "Rapstar," co-written byMurda Beatz.\n"Obi has a bright energy, a way about him that\'s contagious," shared Neil Jacobson, Hallwood Media founder and CEO.
  • "The business he\'s building is going to be a big win for Hallwood and for his clients as he continues to grow.
  • "\n"I\'ve always respected Neil and his passion for innovation," shared Obi.

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021

The presentation slides will be available online at www.obipharma.com on January 12, 2021.

Key Points: 
  • The presentation slides will be available online at www.obipharma.com on January 12, 2021.
  • OBI Pharma, Inc., is a Taiwan biopharmaceutical company that was established in 2002.
  • Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results.
  • Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021

The presentation slides will be available online at www.obipharma.com on January 12, 2021.

Key Points: 
  • The presentation slides will be available online at www.obipharma.com on January 12, 2021.
  • OBI Pharma, Inc., is a Taiwan biopharmaceutical company that was established in 2002.
  • Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results.
  • Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

Retrieved on: 
Monday, September 14, 2020

TAIPEI, Taiwan, Sept. 14, 2020 /PRNewswire/ --OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020.

Key Points: 
  • TAIPEI, Taiwan, Sept. 14, 2020 /PRNewswire/ --OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020.
  • The scientific presentation titled, "A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999" with a follow-up live discussion and question session will be led byMing-Tain Lai, PhD.
  • "OBI Pharma is proud to present at the prestigious 2020 World ADC Digital conference for OBI-999, our novel anti-Globo H first-in-class ADC cancer therapeutic.
  • Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

Retrieved on: 
Monday, September 14, 2020

TAIPEI, Taiwan, Sept. 14, 2020 /PRNewswire/ --OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020.

Key Points: 
  • TAIPEI, Taiwan, Sept. 14, 2020 /PRNewswire/ --OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020.
  • The scientific presentation titled, "A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999" with a follow-up live discussion and question session will be led byMing-Tain Lai, PhD.
  • "OBI Pharma is proud to present at the prestigious 2020 World ADC Digital conference for OBI-999, our novel anti-Globo H first-in-class ADC cancer therapeutic.
  • Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.

Oklahoma Blood Institute (OBI) Hosts "Gone Savin' Lives!" Blood Drive and COVID-19 Antibody Testing Event in Collaboration with DNI

Retrieved on: 
Thursday, August 27, 2020

OKLAHOMA CITY, Aug. 27, 2020 /PRNewswire/ --DNI, a tribally-owned prime contractor, is excited to announce its collaboration with OBI to provide a public blood drive in Oklahoma City on Tuesday, September 1, from 11-4.

Key Points: 
  • OKLAHOMA CITY, Aug. 27, 2020 /PRNewswire/ --DNI, a tribally-owned prime contractor, is excited to announce its collaboration with OBI to provide a public blood drive in Oklahoma City on Tuesday, September 1, from 11-4.
  • OBI will arrive in their "Bloodmobile," parking it in the NE parking lot of the 2000 N. Classen Blvd.
  • t-shirt (colors will vary; while supplies last)
    One choice of the following tickets:
    ONE lucky donor to win a $250 Visa Gift Card!
  • Those interested in donating should schedule an appointment via the OBI donor portal or by calling OBI directly at 877.340.8777.

OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

Retrieved on: 
Wednesday, May 20, 2020

We look forward to providing future updates of our studies, which we believe could offer potential therapeutic benefits to patients suffering from cancer," stated Tillman Pearce, MD, Chief Medical Officer at OBI Pharma.

Key Points: 
  • We look forward to providing future updates of our studies, which we believe could offer potential therapeutic benefits to patients suffering from cancer," stated Tillman Pearce, MD, Chief Medical Officer at OBI Pharma.
  • Presenter:Apostolia Maria Tsimberidou, MD, Ph.D, The University of Texas MD Anderson Cancer Center, Houston, TX
    The above poster presentations will be available online at www.obipharma.com on May 29, 2020.
  • OBI Pharma, Inc., is a Taiwan biopharmaceutical company that was established in 2002.
  • Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.